Research Article
Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis
Table 1
Clinical and demographic characteristics of the study subjects.
| | (%) |
| | Sex | | | Female | 23 (30.3%) | | Male | 53 (69.7%) | | Age | | | Mean (SD) | 56 (7.1) | | Child-Pugh stage | | | A | 28 (36.8%) | | B | 29 (38.2%) | | C | 19 (25.0%) | | MELD | | | Median (IQR) | 14 (9.8 to 16) | | Transplantation waiting time (days) | | | Median (IQR) | 533 (332 to 846) | | Missing data | 5 (6.6%) | | Locoregional therapy before transplantation | 47 (61.8%) | | Transarterial chemoembolization | 37 (48.7%) | | Radio frequency ablation | 5 (6.6%) | | Liver resection | 5 (6.6%) | | Number of red blood cell units transfused during transplantation | | | Median (IQR) | 2.0 (1.0 to 4.0) | | Alpha-fetoprotein (ng/ml) | | | Median (IQR) | 17.2 (5.6 to 67) | | Missing data | 3 (3.9%) | | Number of HCC tumors | | | Single tumor | 23 (30.3%) | | 2-3 tumors | 19 (25.0%) | | 4-5 tumors | 7 (9.2%) | | >5 tumors | 27 (35.5%) | | Total tumor size | | | <5 cm | 37 (48.7%) | | 5-9 cm | 10 (13.2%) | | >9 cm | 29 (38.2%) | | Presence of tumor necrosis | | | Yes | 37 (48.7%) | | Missing data | 1 (1.3%) | | Microvascular invasion | | | Yes | 11 (14.5%) |
|
|
SD: standard deviation; IQR: interquartile range; MELD: Model for End-stage Liver Disease; HCC: hepatocellular carcinoma.
|
